keyword
MENU ▼
Read by QxMD icon Read
search

Durvalumab

keyword
https://www.readbyqxmd.com/read/27764686/concurrent-irradiation-with-the-anti-programmed-cell-death-ligand-1-immune-checkpoint-blocker-durvalumab-single-centre-subset-analysis-from-a-phase-1-2-trial
#1
Antonin Levy, Christophe Massard, Jean-Charles Soria, Eric Deutsch
PURPOSE: To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in combination with radiotherapy (RT) in an expansion cohort of patients included in a phase 1/2 trial at our institution. PATIENTS AND METHODS: Data from patients who received concurrent palliative RT with durvalumab (10 mg/kg every 2 weeks via intravenous infusion) were analysed in terms of safety (CTCAE v4.0) and efficacy (RECIST v1.1 and tumour growth rate [TGR])...
November 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27717372/development-of-a-programmed-cell-death-ligand-1-immunohistochemical-assay-validated-for-analysis-of-non-small-cell-lung-cancer-and-head-and-neck-squamous-cell-carcinoma
#2
Marlon C Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E Steele, Paul B Robbins, John A Blake-Haskins, Jill Walker
BACKGROUND: A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which patients are more likely to respond to anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy. Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by Ventana Medical Systems Inc. and key analytical parameters of its use in formalin-fixed, paraffin-embedded (FFPE) samples of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC)...
October 8, 2016: Diagnostic Pathology
https://www.readbyqxmd.com/read/27623999/novel-immunotherapy-in-the-treatment-of-advanced-non-small-cell-lung-cancer
#3
G Santabarbara, P Maione, A Rossi, G Palazzolo, C Gridelli
INTRODUCTION: Lung cancers remain the principal cause of death cancer-related worldwide with a poor survival rate at five years from diagnosis. In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy. New approaches possibly applicable at the major of patients are needed. AREAS COVERED: The discovery that the immune system plays a fundamental role in the fight against cancer...
September 23, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27532023/pd-l1-biomarker-testing-for-non-small-cell-lung-cancer-truth-or-fiction
#4
REVIEW
Claud Grigg, Naiyer A Rizvi
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA approved for use in certain patients who have failed or progressed on platinum-based or targeted therapies while agents targeting PD-L1, atezolizumab and durvalumab, are approaching the final stages of clinical testing...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27389724/battling-regional-stage-iii-lung-cancer-bumpy-road-of-a-cancer-survivor-in-the-immunotherapy-age
#5
Zhonglin Hao, Paul Biddinger, Carsten Schroeder, Khurram Tariq
A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27321156/anti-pd-l1-inhibitor-durvalumab-in-bladder-cancer
#6
Vicki Brower
No abstract text is available yet for this article.
July 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27269937/safety-and-efficacy-of-durvalumab-medi4736-an-anti-programmed-cell-death-ligand-1-immune-checkpoint-inhibitor-in-patients-with-advanced-urothelial-bladder-cancer
#7
Christophe Massard, Michael S Gordon, Sunil Sharma, Saeed Rafii, Zev A Wainberg, Jason Luke, Tyler J Curiel, Gerardo Colon-Otero, Omid Hamid, Rachel E Sanborn, Peter H O'Donnell, Alexandra Drakaki, Winston Tan, John F Kurland, Marlon C Rebelatto, Xiaoping Jin, John A Blake-Haskins, Ashok Gupta, Neil H Segal
PURPOSE: To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in patients with advanced urothelial bladder cancer (UBC). METHODS: A phase 1/2 multicenter, open-label study is being conducted in patients with inoperable or metastatic solid tumors. We report here the results from the UBC expansion cohort. Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was administered intravenously for up to 12 months...
September 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27265743/a-phase-iii-study-of-durvalumab-medi4736-with-or-without-tremelimumab-for-previously-treated-patients-with-advanced-nsclc-rationale-and-protocol-design-of-the-arctic-study
#8
David Planchard, Takashi Yokoi, Michael J McCleod, Jürgen R Fischer, Young-Chul Kim, Marc Ballas, Kelvin Shi, Jean-Charles Soria
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies have shown promising clinical activity in advanced, refractory non-small-cell lung cancer (NSCLC), but antitumor activity appears to be greater in patients with PD-L1(+) tumors compared with patients harboring PD-L1(-) tumors. Combining the anti-PD-L1 antibody durvalumab and the anti-cytotoxic T-lymphocyte antigen 4 antibody tremelimumab offers the potential for antitumor activity in patients with advanced NSCLC, regardless of PD-L1 tumor status...
May 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27198416/60pd-inhibition-of-pegfr-in-paired-tumour-biopsies-from-tki-treatment-na%C3%A3-ve-egfr-mutant-nsclc-patients-treated-with-gefitinib-egfr-inhibitor-or-gefitinib-in-combination-with-durvalumab-anti-pd-l1
#9
T Yeh, V Jacobs, H Angell, J Geradts, J Hou, J Karakunnel, C Barrett
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27198414/57o-efficacy-safety-and-tolerability-of-medi4736-durvalumab-d-a-human-igg1-anti-programmed-cell-death-ligand-1-pd-l1-antibody-combined-with-gefitinib-g-a-phase-i-expansion-in-tki-na%C3%A3-ve-patients-pts-with-egfr-mutant-nsclc
#10
D L Gibbons, L Q Chow, D-W Kim, S-W Kim, T Yeh, X Song, H Jiang, R Taylor, J Karakunnel, B Creelan
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27198329/192tip-neptune-a-global-phase-3-study-of-durvalumab-medi4736-plus-tremelimumab-combination-therapy-versus-standard-of-care-soc-platinum-based-chemotherapy-in-the-first-line-treatment-of-patients-pts-with-advanced-or-metastatic-nsclc
#11
T Mok, P Schmid, O Arén, O Arrieta, M Gottfried, A R Jazieh, R Ramlau, K Timcheva, C Martin, S McIntosh
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27198327/191tip-mystic-a-global-phase-3-study-of-durvalumab-medi4736-plus-tremelimumab-combination-therapy-or-durvalumab-monotherapy-versus-platinum-based-chemotherapy-ct-in-the-first-line-treatment-of-patients-pts-with-advanced-stage-iv-nsclc
#12
S Peters, S Antonia, S B Goldberg, J V Heymach, E S Kim, K Nakagawa, V Papadimitrakopoulou, P Mukhopadhyay, S McIntosh, N A Rizvi
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27198274/136o-osimertinib-combined-with-durvalumab-in-egfr-mutant-non-small-cell-lung-cancer-results-from-the-tatton-phase-ib-trial
#13
M-J Ahn, J Yang, H Yu, H Saka, S Ramalingam, K Goto, S-W Kim, L Yang, A Walding, G R Oxnard
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27198270/129tip-sakk-16-14-anti-pd-l1-antibody-durvalumab-medi4736-in-addition-to-neoadjuvant-chemotherapy-in-patients-with-stage-iiia-n2-non-small-cell-lung-cancer-nsclc-a-multicenter-single-arm-phase-ii-trial
#14
S I Rothschild, A Zippelius, S Savic Prince, M Gonzalez, W Weder, A Xyrafas, C Rusterholz, M Pless
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27196116/pd-l1-testing-for-lung-cancer-in-the-uk-recognizing-the-challenges-for-implementation
#15
REVIEW
Ian A Cree, Richard Booton, Paul Cane, John Gosney, Merdol Ibrahim, Keith Kerr, Rohit Lal, Conrad Lewanski, Neal Navani, Andrew G Nicholson, Marianne Nicolson, Yvonne Summers
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1). Several drugs targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved or are in the late stages of development. Inevitably, the introduction of these drugs will put pressure on healthcare systems, and there is a need to stratify patients to identify those who are most likely to benefit from such treatment...
August 2016: Histopathology
https://www.readbyqxmd.com/read/27019997/immune-checkpoint-inhibitors-in-lung-cancer-past-present-and-future
#16
Nagashree Seetharamu, Daniel R Budman, Kevin M Sullivan
Inhibitory ligands on tumor cells and their corresponding receptors on T cells are collectively called immune checkpoint molecules and have emerged as druggable targets that harness endogenous immunity to fight cancer. Immune checkpoint inhibitors targeting CTLA-4, PD-1 and PD-L1 have been developed for the treatment of patients with non-small-cell lung cancer and other malignancies, with impressive clinical activity, durable responses and a favorable toxicity profile. This article reviews the development, current status and future directions for some of these agents...
May 2016: Future Oncology
https://www.readbyqxmd.com/read/26928461/autoimmune-bullous-skin-disorders-with-immune-checkpoint-inhibitors-targeting-pd-1-and-pd-l1
#17
Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Klaus Busam, Jane Cunningham, David B Page, Michael A Postow, Alyona Weinstein, Anna Skripnik Lucas, Kathryn T Ciccolini, Elizabeth A Quigley, Alexander M Lesokhin, Paul K Paik, Jamie E Chaft, Neil H Segal, Sandra P D'Angelo, Mark A Dickson, Jedd D Wolchok, Mario E Lacouture
Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAbs cause cutaneous immune-related adverse events. Although the most commonly reported cutaneous toxicities are mild, a subset may persist despite therapy and can lead to severe or life-threatening toxicity. Autoimmune blistering disorders are not commonly associated with immune checkpoint mAb therapy...
May 2016: Cancer Immunology Research
https://www.readbyqxmd.com/read/26882955/immunotherapy-for-small-cell-lung-cancer-emerging-evidence
#18
Martin Reck, David Heigener, Niels Reinmuth
Treatment for small-cell lung cancer (SCLC) has changed little over the past few decades; available therapies have failed to extend survival in advanced disease. In recent years, immunotherapy with treatments such as interferons, TNFs, vaccines and immune checkpoint inhibitors has advanced and shown promise in the treatment of several tumor types. Immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, durvalumab, tremelimumab and ulocuplumab are at the forefront of immunotherapy and have achieved approvals for certain cancer types, including melanoma (ipilimumab, nivolumab and pembrolizumab), non-SCLC (nivolumab and pembrolizumab) and renal cell carcinoma (nivolumab)...
April 2016: Future Oncology
https://www.readbyqxmd.com/read/26880697/immunotherapy-for-gastric-cancer-a-focus-on-immune-checkpoints
#19
Maria Alsina, Markus Moehler, Cinta Hierro, Raquel Guardeño, Josep Tabernero
Gastric cancer (GC) is a major world-wide health problem. It is the third leading cause of death from cancer. The treatment of advanced GC by chemotherapy has limited efficacy. The addition of some targeted therapies like trastuzumab and ramucirumab have added a modest benefit, but only in human epidermal growth factor receptor 2 (ERBB2 or HER2)-positive patients and in the second-line setting, respectively. The development of new and effective therapeutic strategies must consider the genetic complexity and heterogeneity of GC; prognostic and predictive biomarkers should be identified for clinical implementation...
August 2016: Targeted Oncology
https://www.readbyqxmd.com/read/26858122/safety-and-antitumour-activity-of-durvalumab-plus-tremelimumab-in-non-small-cell-lung-cancer-a-multicentre-phase-1b-study
#20
RANDOMIZED CONTROLLED TRIAL
Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel, Naiyer A Rizvi
BACKGROUND: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC). METHODS: We did a multicentre, non-randomised, open-label, phase 1b study at five cancer centres in the USA...
March 2016: Lancet Oncology
keyword
keyword
56677
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"